Triple-Drug cocktail shows promise for untreated lung cancer

NCT ID NCT03573947

Completed Disease control Sponsor: Jeffrey Clarke Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated metastatic non-small cell lung cancer. The goal was to see if the mix could slow cancer growth and be safe. Results may point to a new first-line option, but the study is small and early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo), ipilimumab (Yervoy), and paclitaxel (Taxol)
What this could lead to: If this combination works, it could offer a new first-line treatment option that helps control advanced lung cancer for longer.
What could go wrong: This is a small, early-phase trial (46 people) with no comparison group. The drugs can cause serious immune-related side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.